Emerging Growth Research Maintains Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Strategic U.S. Market Entry

Core Viewpoint - Emerging Growth Research maintains a Buy-Extended rating for SBC Medical Group Holdings, Inc. with a 12-month price target of $9.00, indicating significant upside potential from the current closing price of $4.44 as of January 6, 2026 [1]. Company Developments - SBC Medical Group Holdings has made a strategic minority equity investment and established a structured collaboration framework with OrangeTwist, a prominent U.S.-based MedSpa chain, marking its entry into the United States medical aesthetics market [1].